<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30056">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01833117</url>
  </required_header>
  <id_info>
    <org_study_id>C-12-021</org_study_id>
    <nct_id>NCT01833117</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of FID 119515A</brief_title>
  <official_title>A Randomized, Observer-Masked, Efficacy and Safety Study of FID 119515A in Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of FID 119515A to BlinkÂ®  Tears on the
      integrity of tear film in adults with a history of dry eye in both eyes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who meet the enrollment criteria will be randomized in a 2:1 manner to receive
      treatment with FID 119515A or Blink Tears respectively for this one-day, single-dose study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean change from baseline in tear break-up time (TBUT) at 60 minutes</measure>
    <time_frame>Baseline, 60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fluorescein dye is instilled in the eye to assess tear break-up time. Tear break-up time will be assessed prior to test article instillation (baseline) and at 60 minutes post test article instillation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) of TBUT from 0 to 60 minutes</measure>
    <time_frame>0 to 60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fluorescein dye is instilled in the eye to assess tear break-up time. Tear break-up time will be assessed prior to test article instillation (0 minutes) and at intervals up to 60 minutes post test article instillation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>FID 119515A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in the study eye, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BLINK TEARS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop in the study eye, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FID 119515A topical ocular drops</intervention_name>
    <arm_group_label>FID 119515A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BLINK TEARS topical ocular drops</intervention_name>
    <arm_group_label>BLINK TEARS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign Informed Consent.

          -  At least a 3 month documented history of dry eye in both eyes.

          -  Tear break-up time and Ocular Surface Disease Index Questionnaire score as specified
             in protocol.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Pregnant or breastfeeding.

          -  Any evidence of ocular infection or inflammation within 30 days prior to Screening.

          -  Any ocular surgery.

          -  Ocular trauma requiring medical or pharmacological treatment within 1 year of
             Screening.

          -  Current presence of punctal plugs (permanent or temporary) or previous permanent
             punctal closure by cautery/diathermy.

          -  Use of topical ocular prescription or non-prescription medications within 30 days of
             Screening.

          -  Participation in any other clinical trial within 30 days prior to Screening.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Lindsey, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Call Center at 1-888-451-3937 for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 4, 2013</lastchanged_date>
  <firstreceived_date>April 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry eye</keyword>
  <keyword>Tear film</keyword>
  <keyword>Tear break-up time</keyword>
  <keyword>Ocular surface</keyword>
  <keyword>Eye drops</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
